Open Save New
FeedNavigator / National Library of Health Sciences
 
  
Tutkijat / Oulu
AddAla-Kokko, L.
AddAla-Kokko, T(ero)
AddAla-Korpela, M(ika)
AddAlahuhta, S.
AddAlén, M(arkku)
AddAntikainen, R.
AddAnttonen, V(uokko)
AddBiancari, F(austo)
AddBloigu, R(isto)
AddEskelinen, S.
AddFlinkkilä, T(apio)
AddHakkola, J.
AddHallman, M.
AddHartikainen, A(nna)-L(iisa)
AddHausen, H.
AddHautala, N(ina)
AddHautala, T(imo)
AddHeape, A.
AddHerzig, K(arl)-H(einz)
AddHillbom, M.
AddHiltunen, J.K.
AddHörkko, S.
AddHuikuri, H(eikki)
AddHukkanen J(anne)
AddIgnatius, J.
AddIsohanni, M.
AddJaakkola, J.
AddJaakkola, M(aritta) S.
AddJaakola, V-P.
AddJämsä, T(imo)
AddJanhonen, S.
AddJartti, T(uomas)
AddJärvelin, M(arjo)-R(iitta)
AddJokelainen, J(ari)
AddJuffer, A(ndré) H.
AddJunttila, J(uhani)
AddJuvonen, T.
AddKaarteenaho, R(iitta)
AddKajantie, E(ero)*(THL/OY)
AddKarppinen (Koivunen), P(eppi)
AddKarppinen, J(aro)
AddKarttunen, T.J.
AddKeinänen-Kiukaanniemi, S(irkka)
AddKerkelä, R(isto)
AddKesäniemi, Y(rjö) A(ntero)
AddKettunen, J(ohannes)
AddKietzmann, T(homas).
AddKivirikko, K.I.
AddKnuuttila, M.
AddKoivukangas, J.
AddKursula, P(etri)
AddKyngäs, H.
AddLarivaara, P.
AddLarmas, M.
AddLehenkari, P(etri)
AddLehtiö, L(ari)
AddLeppilahti, J.
AddLuukinen, H.
AddMainio A
AddMajamaa, K.
AddMäki, P(irjo)
AddMäkikallio, T(imo) H.
AddMännikkö, M(inna)
AddManninen, A(ki).
AddMartikainen, H(annu)
AddMiettunen, J(ouko)
AddMyllyharju, J(ohanna)
AddMyllylä, R.
AddMyllylä, V.
AddNäyhä, S(imo)
AddNeubauer, P.
AddNieminen, M(iika) T.
AddNieminen, P(entti)
AddNiinimäki, J(aakko)
AddOhukainen, P(auli)
AddOikarinen, A.
AddOikarinen, K.
AddPelkonen, O(lavi)
AddPetäjä-Repo, U.E.
AddPihlajaniemi, T(aina)
AddPirttiniemi, P(ertti)
AddPuistola, U(lla)
AddRajaniemi, H.J.
AddRäsänen, P.
AddRaustia, A.
AddRemes, A(nne)
AddRisteli, J.
AddRistiniemi, J.
AddRuddock, L.W.
AddRuokonen, A.
AddRyynänen, M.
AddSaarakkala, S.
AddSaari, A.
AddSalo, T(uula)
AddSándor, G(eorge) K.
AddSavolainen, E-R.
AddSavolainen, M.J.
AddSavolainen, O.
AddSillanpää, M(ikko).
AddSoininen, R.
AddSorri, M.
AddTaanila, A.
AddTapiainen, T(erhi)
AddTervonen, O(smo)
AddTimonen, M(arkku)
AddTurpeenniemi-Hujanen, T.
AddTuukkanen, J(uha)
AddTuulonen, A.
AddUhari, M.
AddUkkola, O(lavi)
AddUusimaa, J.
AddVainio, O.
AddVainio, S.
AddVäyrynen, J(uha) P.
AddVeijola, J(uha)
AddVeijola, R(iitta)
AddVirokannas, H.
AddVoipio, H(anna)-M(arja)
AddVuolteenaho, O.
AddWeckström, M.
AddWei, GH.
AddWierenga, R.K.
AddWinqvist, R(obert)
AddYlänne, J.
AddYlitalo, K(ari)

Scholar Chart >>



»My Articles

»Latest Feeds

»Popular Feeds
Search Feed Catalog by Name:
Critique of the "Comment" etitled "Pyrethroid exposure: not so harmless after all" by Demeneix et al. (2020) published in The Lancet Diabetes Endocrinology.Pelkonen, O(lavi)198 dayssaveRefWorks
Statement on the translocation potential by Pseudomonas chlororaphis MA342 in plants after seed treatment of cereals and peas and assessment of the risk to humans.Pelkonen, O(lavi)264 dayssaveRefWorks
Inhibition and induction of CYP enzymes in humans: an update.Pelkonen, O(lavi)268 dayssaveRefWorks
CYP-associated drug-drug interactions: A mission accomplished?Pelkonen, O(lavi)290 dayssaveRefWorks
Scientific Opinion of the Scientific Panel on Plant Protection Products and their Residues (PPR Panel) on the genotoxic potential of triazine amine (metabolite common to several sulfonylurea active substances).Pelkonen, O(lavi)324 dayssaveRefWorks
Scientific statement on the coverage of bats by the current pesticide risk assessment for birds and mammals.Pelkonen, O(lavi)383 dayssaveRefWorks
Scientific Opinion on the setting of health-based reference values for metabolites of the active substance terbuthylazine.Pelkonen, O(lavi)383 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)400 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity: how to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)410 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)439 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)443 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)446 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)446 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)446 dayssaveRefWorks
Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study.Pelkonen, O(lavi)782 dayssaveRefWorks
Integration of epidemiological findings with mechanistic evidence in regulatory pesticide risk assessment: EFSA experiences.Pelkonen, O(lavi)810 dayssaveRefWorks
Editorial.Pelkonen, O(lavi)920 dayssaveRefWorks
Establishing a systematic framework to characterise in vitro methods for human hepatic metabolic clearance.Pelkonen, O(lavi)1076 dayssaveRefWorks
Obfuscating Transparency?Pelkonen, O(lavi)1102 dayssaveRefWorks
Toxicology meets Pharmacodynamics and Pharmacokinetics - New Concepts, Models and In Vitro Approaches and Tools.Pelkonen, O(lavi)1123 dayssaveRefWorks
CYP Induction and Xeno-Sensing Receptors PXR, CAR, AHR and PPARα at the Crossroads of Toxicokinetics and Toxicodynamics.Pelkonen, O(lavi)1230 dayssaveRefWorks
Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research.Pelkonen, O(lavi)1520 dayssaveRefWorks
Cardiac safety of ophthalmic timolol.Pelkonen, O(lavi)1737 dayssaveRefWorks
Upholding science in health, safety and environmental risk assessments and regulations.Pelkonen, O(lavi)1770 dayssaveRefWorks
Cardiac safety of ophthalmic timolol.Pelkonen, O(lavi)1800 dayssaveRefWorks
Response to“The Path Forward on Endocrine Disruptors Requires Focus”.Pelkonen, O(lavi)1888 dayssaveRefWorks
Tandem mass spectrometric analysis of S- and N-linked glutathione conjugates of pulegone and menthofuran and identification of P450 enzymes mediating their formation.Pelkonen, O(lavi)1960 dayssaveRefWorks
Metabolism and metabolite profiles in vitro and in vivo of ospemifene in humans and preclinical species.Pelkonen, O(lavi)2075 dayssaveRefWorks
Differentiation-Promoting Medium Additives for Hepatocyte Cultivation and Cryopreservation.Pelkonen, O(lavi)2171 dayssaveRefWorks
Formation of GSH-trapped reactive metabolites in human liver microsomes, S9 fraction, HepaRG-cells, and human hepatocytes.Pelkonen, O(lavi)2174 dayssaveRefWorks
Drug Metabolism - From In Vitro to In Vivo, from Simple to Complex Reflections of the BCPT Nordic Prize 2014 Awardee.Pelkonen, O(lavi)2231 dayssaveRefWorks
Principles of Pharmacology and Toxicology Also Govern Effects of Chemicals on the Endocrine System.Pelkonen, O(lavi)2245 dayssaveRefWorks
Very low mammographic breast density predicts poorer outcome in patients with invasive breast cancer.Pelkonen, O(lavi)2334 dayssaveRefWorks
Biotransformation in vitro: An essential consideration in the quantitative invitro-to-in vivo extrapolation (QIVIVE) of toxicity data.Pelkonen, O(lavi)2426 dayssaveRefWorks
Reactive Metabolites in Early Drug Development: Predictive in Vitro Tools.Pelkonen, O(lavi)2475 dayssaveRefWorks
Why is Research on Herbal Medicinal Products Important and How Can We Improve Its Quality?Pelkonen, O(lavi)2612 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)2752 dayssaveRefWorks
Human variation and CYP enzyme contribution in benfuracarb metabolism in human in vitro hepatic models.Pelkonen, O(lavi)2874 dayssaveRefWorks
Analytical challenges for conducting rapid metabolism characterization for QIVIVE.Pelkonen, O(lavi)2882 dayssaveRefWorks
Open letter to the European commission: scientifically unfounded precaution drives European commission's recommendations on EDC regulation, while defying common sense, well-established science, and risk assessment principles.Pelkonen, O(lavi)2888 dayssaveRefWorks
Comparative metabolism of benfuracarb in in vitro mammalian hepatic microsomes model and its implications for chemical risk assessment.Pelkonen, O(lavi)2895 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)2909 dayssaveRefWorks
Estimation of health risk by using toxicokinetic modelling: A case study of polychlorinated biphenyl PCB153.Pelkonen, O(lavi)2910 dayssaveRefWorks
Effects of ospemifene on drug metabolism mediated by cytochrome p450 enzymes in humans in vitro and in vivo.Pelkonen, O(lavi)2922 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)2927 dayssaveRefWorks
Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.Pelkonen, O(lavi)2931 dayssaveRefWorks
"Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.''Pelkonen, O(lavi)2931 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)2937 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)2938 dayssaveRefWorks
Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations.Pelkonen, O(lavi)2972 dayssaveRefWorks
 XML / RSS feed
report
next »